These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Hughes DA; Vilar FJ; Ward CC; Alfirevic A; Park BK; Pirmohamed M Pharmacogenetics; 2004 Jun; 14(6):335-42. PubMed ID: 15247625 [TBL] [Abstract][Full Text] [Related]
50. [Prospective validation of a pharmacogenetic test: the PREDICT-1 study]. Muñoz de Benito RM; Arribas López JR Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():40-4. PubMed ID: 18680695 [TBL] [Abstract][Full Text] [Related]
51. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. Kauf TL; Farkouh RA; Earnshaw SR; Watson ME; Maroudas P; Chambers MG Pharmacoeconomics; 2010; 28(11):1025-39. PubMed ID: 20575592 [TBL] [Abstract][Full Text] [Related]
52. HLA-B*5701 Genotyping for Abacavir Prescription: Re-Examination of its Cost-Effectiveness in Singapore. Goh KS; Kapoor R; Lee CC; Ng CY; Leong KP Ann Acad Med Singap; 2019 Apr; 48(4):133-138. PubMed ID: 31131386 [No Abstract] [Full Text] [Related]
53. Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore? Kapoor R; Martinez-Vega R; Dong D; Tan SY; Leo YS; Lee CC; Sung C; Ng OT; Archuleta S; Teo YY Pharmacogenet Genomics; 2015 Feb; 25(2):60-72. PubMed ID: 25461248 [TBL] [Abstract][Full Text] [Related]
54. Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care. De Spiegelaere W; Philippé J; Vervisch K; Verhofstede C; Malatinkova E; Kiselinova M; Trypsteen W; Bonczkowski P; Vogelaers D; Callens S; Ruelle J; Kabeya K; De Wit S; Van Acker P; Van Sandt V; Emonds MP; Coucke P; Sermijn E; Vandekerckhove L PLoS One; 2015; 10(4):e0123525. PubMed ID: 25874872 [TBL] [Abstract][Full Text] [Related]
55. HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA Mounzer K; Hsu R; Fusco JS; Brunet L; Henegar CE; Vannappagari V; Stainsby CM; Shaefer MS; Ragone L; Fusco GP AIDS Res Ther; 2019 Jan; 16(1):1. PubMed ID: 30651100 [TBL] [Abstract][Full Text] [Related]
56. Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART. Munderi P; Snowden WB; Walker AS; Kityo C; Mosteller M; Kabuye G; Thoofer NK; Ssali F; Gilks CF; Hughes AR; Trop Med Int Health; 2011 Feb; 16(2):200-4. PubMed ID: 21091860 [TBL] [Abstract][Full Text] [Related]
57. Prevalence of HLA-B*5701 in HIV-infected patients in Spain (results of the EPI Study). Arrizabalaga J; Rodriguez-Alcántara F; Castañer JL; Ocampo A; Podzamczer D; Pulido F; Riera M; Sanz J; Pascual-Bernaldez M; Dal-Re R; HIV Clin Trials; 2009; 10(1):48-51. PubMed ID: 19362996 [TBL] [Abstract][Full Text] [Related]
58. Labeling changes for abacavir. AIDS Patient Care STDS; 2008 Aug; 22(8):683-4. PubMed ID: 18721055 [No Abstract] [Full Text] [Related]
59. The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions. Airo P; Scarsi M; Malagoli A; Carella G; Izzo I; Carosi G; Torti C J Acquir Immune Defic Syndr; 2009 Jul; 51(3):361-2. PubMed ID: 19553774 [No Abstract] [Full Text] [Related]